345 related articles for article (PubMed ID: 33106165)
1. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
2. PTEN loss correlates with T cell exclusion across human cancers.
Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
[TBL] [Abstract][Full Text] [Related]
3. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Sweis RF; Spranger S; Bao R; Paner GP; Stadler WM; Steinberg G; Gajewski TF
Cancer Immunol Res; 2016 Jul; 4(7):563-8. PubMed ID: 27197067
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic signatures of tumors undergoing T cell attack.
Gokuldass A; Schina A; Lauss M; Harbst K; Chamberlain CA; Draghi A; Westergaard MCW; Nielsen M; Papp K; Sztupinszki Z; Csabai I; Svane IM; Szallasi Z; Jönsson G; Donia M
Cancer Immunol Immunother; 2022 Mar; 71(3):553-563. PubMed ID: 34272988
[TBL] [Abstract][Full Text] [Related]
5. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
6. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Kim A; Lim SM; Kim JH; Seo JS
Front Immunol; 2021; 12():598671. PubMed ID: 33717076
[TBL] [Abstract][Full Text] [Related]
7. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Spranger S
Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
10.
Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
Front Immunol; 2020; 11():1620. PubMed ID: 32903763
[No Abstract] [Full Text] [Related]
11. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
13. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in
Li Z; Lin J; Zhang L; Li J; Zhang Y; Zhao C; Wang H
Future Oncol; 2020 Oct; 16(29):2295-2306. PubMed ID: 32639175
[No Abstract] [Full Text] [Related]
15. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Danaher P; Warren S; Lu R; Samayoa J; Sullivan A; Pekker I; Wallden B; Marincola FM; Cesano A
J Immunother Cancer; 2018 Jun; 6(1):63. PubMed ID: 29929551
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
18. Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.
Roller A; Davydov II; Schwalie PC; Serrano-Serrano ML; Heller A; Staedler N; Ferreira CS; Dietmann G; Klaman I; Valdeolivas A; Korski K; Cannarile MA
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649280
[TBL] [Abstract][Full Text] [Related]
19. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
